Use and handling safety of Mini-Spike 2® chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

We wanted to evaluate the impact of Mini-Spike 2® Chemo + Puresite (MSCP) use on contamination surface levels, professionals’ satisfaction and compounding time at pharmacy compared with Phaseal™. Presence of cyclophosphamide (CYP) and 5-fluorouracil (5FU) was evaluated at three sampling times: basel...

Full description

Saved in:
Bibliographic Details
Published in:Regulatory toxicology and pharmacology 2018-12, Vol.100, p.1-6
Main Authors: García, Silvia Valero, Clérigues, Nieves Vila, Ferrer, Victoria Fornés, Briz, Eduardo López, Andrés, Jose Luis Poveda
Format: Article
Language:English
Subjects:
Antineoplastic Agents - analysis
Chemotherapy
Compounding
Cyclophosphamide - analysis
Drug transfer device
Environmental Monitoring
Equipment Contamination
Filtration - instrumentation
Fluorouracil - analysis
Nursing Staff, Hospital
Occupational Exposure - prevention & control
Occupational health
Pharmacy
Pharmacy Service, Hospital
Surveys and Questionnaires
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We wanted to evaluate the impact of Mini-Spike 2® Chemo + Puresite (MSCP) use on contamination surface levels, professionals’ satisfaction and compounding time at pharmacy compared with Phaseal™. Presence of cyclophosphamide (CYP) and 5-fluorouracil (5FU) was evaluated at three sampling times: baseline; after a decontamination procedure and six months after MSCP use for CYP and 5FU compounding. Testing was carried out using an independent laboratory and wipe testing kit. To test compounding time, four different nurses followed the same compounding protocol with each device. We also developed a questionnaire to obtain feedback from the nurses. We did not find statistically significant differences in the median contamination surface levels between basal and final sampling time, CYP (0.140; 95% CI -1.135, 1.601), 5FU (−0.506; 95% CI -1.756, 0.287). We observed a difference of 10 s on compounding times between the two devices tested (p 
ISSN:0273-2300
1096-0295
DOI:10.1016/j.yrtph.2018.10.002